Tavneos – EMA recommends revocation of marketing authorisation in the EU
16/07/2026
Medicines for human use
Direct healthcare professional communication (DHPC)
The EMA’s human medicines committee has concluded its review of the medicine Tavneos (avacopan) and has recommended that the medicine’s marketing authorisation in the European Union be revoked because its benefits are no longer proven to outweigh its risks.
Healthcare professionals can find further information in the Direct Healthcare Professional Communication (DHPC) on this webpage and on the EMA website.
Patients can also consult the EMA website for more information and should speak to their doctor if they have questions.